GLP-1 drugs and gastroparesis: separating real risk from TikTok panic

What did @drdondiego actually say?

Dr. Dondiego responded to a CNN article about GLP-1 users developing gastroparesis, and he was careful not to overreach. His core argument: gastroparesis requires both objective evidence of delayed gastric emptying on a gastric emptying scan AND symptomatic distress. He drew a line between "therapeutic delayed gastric emptying" caused by GLP-1s and actual gastroparesis, and he noted that medication-induced gastroparesis typically resolves when the drug is stopped. He also pushed patients with severe symptoms to stay in contact with their doctor. For a TikTok duet responding to a CNN scare piece, that's a measured, clinically grounded take.

Does the science back this up?

Yes, mostly. The diagnostic criteria he cited are accurate. Gastroparesis requires documented delayed gastric emptying, usually via a standardized four-hour scintigraphy study, plus symptoms. That is consistent with the American College of Gastroenterology guidelines (Camilleri et al., 2013, American Journal of Gastroenterology). His point about GLP-1 medications slowing gastric emptying as a feature, not just a bug, is also well-supported. Semaglutide delays gastric emptying as part of its mechanism, reducing post-meal glucose spikes (Nauck et al., 2011, Diabetes, Obesity and Metabolism). The complication is distinguishing that expected physiological effect from pathological gastroparesis, which is genuinely difficult in clinical practice and something he only partially addressed.

• GLP-1 receptor agonists slow gastric emptying through vagal pathways and direct gastric effects.
• A 2023 JAMA study (Sodhi et al., 2023, JAMA) found GLP-1 users had a higher risk of gastroparesis diagnosis compared to bupropion-naltrexone users, though absolute risk remained low.
• The same study found increased rates of pancreatitis and bowel obstruction, which he did not mention.

What did they get wrong (or right)?

He got the diagnostic framework right, and his clinical instinct to tell patients not to white-knuckle severe symptoms is sound. The claim that "in the majority of patients GLP-1 medications are well tolerated" is accurate based on trial data, though "well tolerated" in clinical trials still includes substantial nausea rates, up to 44% in SUSTAIN-6 (Marso et al., 2016, New England Journal of Medicine).

Where he was incomplete: he said medication-induced gastroparesis "typically" resolves on discontinuation. That is probably true but the evidence base for full reversal is limited. The 2023 Sodhi JAMA study raised questions about whether some GLP-1-associated gastroparesis persists. He also did not mention that the gastric emptying scan findings in GLP-1 users can look like gastroparesis even without clinical disease, which creates real diagnostic confusion that clinicians are still working through.

What should you actually know?

The CNN story that prompted this video was not fabricated, but it was anecdotal. Case reports and news stories about gastroparesis in GLP-1 users reflect a real signal that researchers are taking seriously. The Sodhi et al. 2023 JAMA study, which is the most cited evidence on this, found a roughly 3-4 times higher risk of gastroparesis diagnosis in GLP-1 users compared to a weight-loss medication control group. That sounds alarming until you see the absolute numbers: still a rare outcome in a large population.

What matters clinically is that patients should not ignore persistent severe nausea, vomiting, or abdominal pain on these medications. Those symptoms can reflect the drug doing its job, or they can be a signal of something going wrong. That distinction requires a real clinical conversation, not a TikTok comment, and Dr. Dondiego said exactly that. Credit where it is due.

• Do not self-diagnose gastroparesis based on GLP-1 side effects alone.
• A formal gastric emptying scan is required for diagnosis, not symptoms alone.
• If symptoms are severe or persistent, contact your prescribing clinician before stopping the medication on your own.